

Supplementary Table 1. Baseline characteristics of study cohort based on study sites

Variable	India (n=278)	Italy (n=386)	Singapore (n=262)	China (n=233)
Age (years)	48±13	64±12	55±10	50±12
Gender, male	201 (72.3)	222 (57.5)	214 (81.7)	139 (60.0)
Ethnicity				
Caucasian	0 (0.0)	356 (92.2)	1 (0.4)	0 (0.0)
Chinese	0 (0.0)	0 (0.0)	95 (36.3)	233 (100.0)
Indian	278 (100.0)	0 (0.0)	32 (12.2)	0 (0.0)
Malay	0 (0.0)	0 (0.0)	111 (42.4)	0 (0.0)
Arabic	0 (0.0)	28 (7.3)	0 (0.0)	0 (0.0)
Others	0 (0.0)	2 (0.5)	23 (8.8)	0 (0.0)
Etiology				
Hepatitis B	73 (26.3)	0 (0.0)	32 (12.2)	142 (60.9)
Hepatitis C	46 (16.6)	386 (100.0)	175 (66.8)	43 (18.5)
Alcohol	90 (32.4)	0 (0.0)	4 (1.5)	11 (4.7)
NASH	69 (24.8)	0 (0.0)	32 (12.2)	1 (0.4)
Others	0 (0.0)	0 (0.0)	19 (7.3)	36 (15.5)
MELD score	9±3	8±2	8±3	8±3
Child-Turcott-Pugh score	5.4±0.7	5.1±0.2	5.2±0.6	5.3±0.7
LSM (kPa)	29.3±10.8	20.0±9.0	23.7±14.0	23.5±3.8
Fibrosis-4	4.3±2.9	5.3±3.7	3.5±3.4	4.3±4.1
Laboratory parameters				
Albumin (g/L)	36±5	42±4	41±5	42±5
Bilirubin (µmol/L)	24±12	15±9	18±20	22±16
ALT (µmol/L)	48±26	100±78	71±40	79±74
Platelets (×10 ³ /µL)	130±66	141±67	164±67	129±57
Platelet count (×10 ³ /µL)				
<150	183 (65.8)	241 (62.4)	125 (47.7)	159 (68.2)
≥150	95 (34.2)	145 (37.6)	137 (52.3)	74 (31.8)
INR	1.16±0.14	1.07±0.10	1.06±0.14	1.09±0.14
Creatinine (µmol/L)	66 (53–80)	69 (60–80)	79 (67–95)	60 (49–67)
Esophageal varices				
No varices	127 (45.7)	197 (69.6)	194 (74.0)	123 (52.8)
Low-risk varices	151 (54.3)	79 (27.9)	48 (18.3)	79 (33.9)
High-risk varices	0 (0.0)	7 (2.5)	20 (7.6)	31 (13.3)
Follow-up time (months)	33 (26–40)	52 (39–56)	43 (32–54)	38 (30–43)

Values are presented as mean±standard deviation, median (interquartile range), or frequency (%).

CSPH, clinically significant portal hypertension; MELD, Model of End-stage Liver Disease; LSM, liver stiffness measurement; ALT, alanine aminotransferase; INR, international normalized ratio.